•
Jun 30, 2020
Ionis Q2 2020 Earnings Report
Ionis reported financial results for Q2 2020, highlighting commercial and R&D revenue growth and a strong cash position.
Key Takeaways
Ionis Pharmaceuticals reported a net loss of $32 million on a GAAP basis but achieved net income of $8 million on a non-GAAP basis. The company saw growth in commercial and R&D revenues and maintained a strong cash position of over $2.3 billion.
Achieved net income on a non-GAAP basis.
Commercial revenue from SPINRAZA royalties increased to $72 million.
Product sales from TEGSEDI and WAYLIVRA increased to $16 million.
R&D revenue increased to more than $55 million.
Ionis
Ionis
Ionis Revenue by Segment
Forward Guidance
Ionis is maintaining its 2020 financial guidance and expects revenue and earnings growth in the second half of this year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income